Therapeutic Armamentarium and Health System Coverage of Multiple Sclerosis in Latin America

Gracia, Fernando; Armién, Blas

doi:10.1159/000337162

Cited by 11 publications

(16 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While fingolimod is now approved in 13 Latin American countries, some data suggest that it is not yet fully available. For example, an unofficial survey conducted at meetings in Colombia and Ecuador in 2011 found that fingolimod was available in only four of the 20 countries included in the analysis, compared with all 20 countries having access to IFNβ (Table 3 ) [ 63 ]. However, it is reasonable to assume that there have been improvements in fingolimod availability in Latin America since 2011, with further improvements expected over the next few years.…”

Section: Discussion: Interpretation and Implicationsmentioning

confidence: 99%

Use of Fingolimod in the Management of Relapsing–Remitting Multiple Sclerosis: Experience from Latin America

Correale

Flores

Bonitto³

et al. 2015

Adv Ther

View full text Add to dashboard Cite

show abstract

Section: Discussion: Interpretation and Implicationsmentioning

confidence: 99%

Use of Fingolimod in the Management of Relapsing–Remitting Multiple Sclerosis: Experience from Latin America

Correale

Flores

Bonitto³

et al. 2015

Adv Ther

View full text Add to dashboard Cite

show abstract

“…This therapeutic option is perhaps motivated by the cost and frequent unreliability in supply of established DMTs (Table 2). 27 Access to therapy in Mexico remains low (≥42.8%), despite healthcare and services provided by the Public Health Ministry, four large SSIs, and private practices to more than 21,000 identified MS patients in the country. 28,29 Mexico along with Argentina, Brazil, Chile, and Colombia are the only countries in the region where all FDA-approved DMTs, up to the first quarter of 2017, are theoretically available.…”

Section: Access To Ms Care Servicesmentioning

confidence: 99%

Access and barriers to MS care in Latin America

Rivera

Macias

2017

Multiple Sclerosis Journal - Experimental, Translational and Cl

View full text Add to dashboard Cite

Multiple sclerosis (MS), an epidemiologically emergent disorder in Latin America (LATAM), poses substantial socioeconomic challenges to a region where most countries remain as economies in development. MS is not health priority despite its economic and communitarian impact with a relatively low prevalence. MS treatments in LATAM have evolved from earlier long-term oral steroids and immunosuppression protocols, to platform disease modifying therapies (DMTs), to the current landscape with more advanced therapeutic molecules. Following FDA approval, a DMT may eventually become available in LATAM conditioned to industrial marketing interest. Most countries do not count all medications in their armamentarium. Access to therapy by the MS population in the region is low (9.5%–42.8%). Generic treatments, biosimilars, and follow-on complex non-biological drugs (CNBD) are commonly available in institutional formularies in LATAM despite their lack of supportive efficacy and safety data and reported molecular differences with the innovators. Savings to health systems thus far have been negligible. Medicine licensing agencies in LATAM, despite limitations in resources, have considerably improved their assessments by incorporating more modern criteria and methodology. Access to symptomatic management, rehabilitation procedures, and the role of patients associations are discussed.

show abstract

“…Treatment issues of multiple sclerosis (MS) in Latin America (LA) have recently been addressed [1,2]. Some particular features of the health systems, patients and medical providers are scarcely described.…”

Section: Tablementioning

confidence: 99%

“…In 2011, experts estimated that below 35% of the LA population had access to DMDs [2]. In contrast, KOL now estimate greater proportions of their patients accessing these treatments.…”

Section: Tablementioning

confidence: 99%